C 0021158
Alternative Names: C-0021158Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator AstraZeneca; Cancer Research UK
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action Arginase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
- 03 Sep 2020 Early research in Cancer in United Kingdom (Parenteral) prior to September 2020
- 25 Sep 2014 AstraZeneca and Cancer Research UK agree to co-promote and co-develop C 0021158 in for Cancer